Therapeutic effect of cyclin-dependent kinase 4/6 inhibitor on dermal fibrosis in murine models of systemic sclerosis.

Akio YamamotoTetsuya SaitoTadashi HosoyaKimito KawahataYoshihide AsanoShinichi SatoFumitaka Mizoguchi Shinsuke YasudaHitoshi Kohsaka

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

We demonstrated the therapeutic effect of CDKI on dermal fibrosis in monotherapy or in combination with TGFβRI. CDKI should be a novel agent for the treatment of SSc, which may be used with TGFβRI to increase the efficacy.

Keyphrases

systemic sclerosis
interstitial lung disease
transforming growth factor
combination therapy
cell cycle
wound healing
rheumatoid arthritis
clinical trial
open label
cell death
idiopathic pulmonary fibrosis
signaling pathway
smoking cessation